> ## Content Index
> Fetch the complete content index at: https://www.consumernews.ai/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 Lawsuit & News Tracker: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity
- URL: https://www.consumernews.ai/glp-1-lawsuit-news-tracker-ozempic-wegovy-mounjaro-zepbound-trulicity/
- Published: 2026-07-04T16:54:12.000Z
- Updated: 2026-08-07T12:58:22.000Z
- Description: The GLP-1 family of drugs might be the biggest thing since AI. There have been unexpected benefits and about as many unexpected problems.
- Author: James R. Hood
- Tags: Health, Consumer Protection

[Could Ozempic-like drugs curb alcohol addiction? VA launches major trialThe Department of Veterans Affairs is launching a large Phase 3 trial of semaglutide as a treatment for alcohol use disorder.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-12c27602-f8be-46ec-a91f-593b6cf1925c.png)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/alcohol-glp1-midj-2026-0c06831c-40db-4907-bbe9-1b526920af4d.jpg)](https://www.consumernews.ai/could-ozempic-like-drugs-curb-alcohol-addiction-va-launches-major-trial/)

August 7, 2026

[Skinny but bald? GLP-1 drugs linked to increased risk of hair lossA large study found that people taking GLP-1 drugs were more likely to be diagnosed with hair loss than patients using two other common classes of diabetes medication.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-0b431551-6987-424c-bcad-54394350142e.png)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/bald-but-skinny-midj-2026-2617b313-aff7-4f0f-af68-2e1e87d0db70.jpg)](https://www.consumernews.ai/skinny-but-bald-glp-1-drugs-linked-to-increased-risk-of-hair-loss/)

July 26, 2026

[Denied coverage? Seven steps to appeal a GLP-1 decisionAn insurance denial does not always mean the case is closed. Patients seeking coverage for Wegovy, Zepbound or another GLP-1 medication may have several opportunities to challenge the decision.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-e8e9c052-dc1d-4cd3-adda-0d722e82cc02.png)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/insurance-says-no-midj-2026-1d31b47b-cfe0-4b7c-a511-4f606ac2ae90.jpg)](https://www.consumernews.ai/denied-coverage-seven-steps-to-appeal-a-glp-1-decision/)

July 21, 2026

[GLP-1 weight-loss drugs may be worth the price — but insurers still say they can’t afford themThe drugs may deliver good value for each patient, but covering everyone who qualifies could overwhelm health-plan budgets.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-b1583591-39c1-4781-ba6f-6e15caaf2b5d.png)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/glp1-costs-midj-2026-c79c7e3c-c9e3-4c14-9361-a479cc641131.jpg)](https://www.consumernews.ai/glp-1-weight-loss-drugs-may-be-worth-the-price-but-insurers-still-say-they-cant-afford-them/)

July 21, 2026

[Implant could eliminate weekly GLP-1 weight-loss shots - but it’s still years awayThe goal is to solve one of the biggest problems with GLP-1 drugs: patients quitting treatment because of cost, side effects or injection fatigue.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-26d9d3e3-a502-452c-9f38-7900b3c1fb3f.png)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/glp-1-injection-midj-2026-fc5371a4-fd15-44de-96a3-8b49c786d5e6.jpg)](https://www.consumernews.ai/implant-could-eliminate-weekly-glp-1-weight-loss-shots-but-its-still-years-away/)

July 12, 2026

[Litigators jockey for advantage as MDL 3094, 3163 GLP-1 court cases maneuver through pretrialAttorneys on both sides of MDL 3094 and MDL 3163 are maneuvering and jockeying for position as multi-district litigation against the makers of GLP-1 drugs including Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro edges closer to actual testimony. The cases break down into two categories: those claiming gastrointestinal injury![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/cnai-logo-icon-600-sq-fdc07ea6-ba10-41ca-9423-5dd7bae7081d.png)ConsumerNews.aiJames R. Hood![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/mdl-litigation-midj-2026-05e649ec-4815-4e2e-8257-905dd7225f36.jpg)](https://www.consumernews.ai/litigators-jockey-for-advantage-as-mdl-3094-3163-glp-1-court-cases-maneuver-through-pretrial/)

July 6, 2026

[$50 Medicare GLP-1 ‘bridge’ presents a difficult entry processThe GLP-1 “bridge” is confusing to get into and its benefits are questionable given its temporary nature.![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-ab8a7913-3577-4e81-85a2-217997119be2.ico)ConsumerNews.aiJames R. Hood![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/glp1-senior-midj-2026-241c7e9e-f473-4375-a407-e17a25e5f19f.jpg)](https://www.consumernews.ai/50-medicare-glp-1-bridge-presents-a-difficult-entry-process/)

July 3, 2026

[Medicare opens first weight-loss coverage at $50 a monthA new pilot Medicare program, “set to continue through 2027, will allow older adults to access GLP-1 medications for $50 per month” — the first time the program will cover them specifically for weight loss,![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-c9fd2f0e-534f-4060-8e00-86e1f5ce0c46.ico)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/weight-loss-efforts-midj-2026-c0fc7518-03f3-4143-82e2-076015c25696.jpg)](https://www.consumernews.ai/medicare-opens-first-weight-loss-coverage-at-50-a-month/)

June 25, 2026

[FDA cracks down on telehealth weight-loss drug marketingRegulators say some firms falsely implied their products were equivalent to FDA-approved medications such as Wegovy, Ozempic, Zepbound, and Mounjaro. The U.S. Food and Drug Administration has intensified its campaign against the booming online weight-loss drug industry, issuing warning letters to 25 telehealth companies that allegedly made![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-dedc4062-8172-4fa2-9ff2-81ed56bfd6f9.ico)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/glp-1-meds-midj-2025-292b3ad0-5d11-4669-8d22-0ee6e20f7986.jpg)](https://www.consumernews.ai/fda-cracks-down-on-telehealth-weight-loss-drug-marketing/)

June 19, 2026

[GLP-1 drugs are reshaping the world while raising longterm questionsPowerful new GLP-1 weight‑loss drugs promise longer, healthier lives for millions of people — but they are also reshaping everything from insurance premiums to clothing racks, while raising fresh questions about safety, cost and who gets access to the “Ozempic revolution.”![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-720006d9-c8bf-441a-a190-405803500595.ico)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/GLP-1-injection-pen-close-up-shot-ef98e82a-ab37-4d5c-be02-e73bcdfe0adf.png)](https://www.consumernews.ai/glp-1-drugs-are-reshaping-the-world-while-raising-longterm-questions/)

June 5, 2026

[GLP-1 Drug Lawsuits Swell Past 3,600 Cases as Courts Tighten Proof StandardsThe cases involve Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity Federal litigation over the blockbuster class of GLP-1 drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity has ballooned to more than 3,600 pending cases across two multidistrict proceedings, as a federal judge moves to tighten the medical evidence![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-628ccd68-032c-41e7-b3cf-0bc6750db084.ico)ConsumerNews.aiThe Editors![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/ozempic-ba-midj-2026-6d7acfca-35f6-4799-bb4d-ba18285f613e.jpg)](https://www.consumernews.ai/glp-1-drug-lawsuits-swell-past-3-600-cases-as-courts-tighten-proof-standards/)

May 9, 2026

[GLP-1 may protect against heart attacks and strokes, UK study findsThe popular diabetes and weight-loss drugs may also help prevent Alzheimer’s, according to one study![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-cb61c741-1743-4caf-9d52-1c6855a25444.ico)ConsumerNews.aiJames R. Hood![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/314988e3-046a-4a0c-a081-4fa4af5caceb_1456x816-jpeg-99e17c7c-b099-451d-b95c-d24098bcf137.jpg)](https://www.consumernews.ai/glp-1-may-protect-against-heart-attacks/)

May 5, 2026

[GLP-1 drugs beef up their Super Bowl pitchesOzempic, Wagovy, Mounjaro, Zepbound take the field, with ‘compounded’ versions at their heels![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-4be8ecf5-670b-4230-a7a2-2c500fb869e7.ico)ConsumerNews.aiJames R. Hood![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/7056edbd-bc15-4a64-bc3d-d72f00b620dc_1315x982-jpeg-ca2c8ba7-8b93-427f-b81c-e26ba65cb7b5.jpg)](https://www.consumernews.ai/glp-1-drugs-beef-up-their-super-bowl/)

Feb. 8, 2026

[Microdosing GLP-1: Too little of a good thing?Marketers and their publicists are hawking tiny doses of GLP-1 but there’s no evidence it’s effective![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/icon/favicon-feeec613-d035-4c8f-b212-08ae2251fd81.ico)ConsumerNews.aiJames R. Hood![](https://storage.ghost.io/c/2a/11/2a11693a-adfd-404e-b346-dc871787142e/content/images/thumbnail/98a6e6dc-ebc0-4e1a-b8a9-0630763ef1d5_819x644-jpeg-cfd1e587-88c5-420a-8798-248de3afbd81.jpg)](https://www.consumernews.ai/microdosing-glp-1-too-little-of-a/)

Jan. 16, 2026